Steroidogenic Enzymes and Stem Cell Markers Are Upregulated during Androgen Deprivation in Prostate Cancer
Authors:
Open Access
- 22 February 2011
- journal article
- research article
- Published by Springer Nature in Molecular Medicine
- Vol. 17 (7-8) , 657-664
Abstract
Considerable levels of testosterone and dihydrotestosterone (DHT) are found in prostate cancer (PCa) tissue after androgen deprivation therapy. Treatment of surviving cancer-initiating cells and the ability to metabolize steroids from precursors may be the keystones for the appearance of recurrent tumors. To study this hypothesis, we assessed the expression of several steroidogenic enzymes and stem cell markers in clinical PCa samples and cell cultures during androgen depletion. Gene expression profiles were determined by microarray or qRT-PCR. In addition, we measured cell viability and analyzed stem cell marker expression in DuCaP cells by immunocytochemistry. Seventy patient samples from different stages of PCa, and the PCa cell line DuCaP were included in this study. The androgen receptor (AR) and enzymes (AKR1C3, HSD17B2, HSD17B3, UGT2B15 and UGT2B17 ) that are involved in the metabolism of adrenal steroids were upregulated in castration resistant prostate cancer (CRPC). In vitro, some DuCaP cells survived androgen depletion, and eventually gave rise to a culture adapted to these conditions. During and after this transition, most of the steroidogenic enzymes were upregulated. These cells also are enriched with stem/progenitor cell markers cytokeratin 5 (CK5) and ATP-binding cassette sub-family G member 2 (ABCG2). Similarly, putative stem/progenitor cell markers CK5, c-Kit, nestin, CD44, c-met, ALDH1A1, α2-integrin, CD133, ABCG2, CXCR4 and POU5F1 were upregulated in clinical CRPC. The upregulation of steroidogenic enzymes and stem cell markers in recurrent tumors suggests that cancer initiating cells can expand by adaptation to their T/DHT deprived environment. Therapies targeting the metabolism of adrenal steroids by the tumor may prove effective in preventing tumor regrowth.Keywords
This publication has 21 references indexed in Scilit:
- An in vitro model for preclinical testing of endocrine therapy combinations for prostate cancerThe Prostate, 2010
- Expression of Pluripotent Stem Cell Reprogramming Factors by Prostate Tumor Initiating CellsJournal of Urology, 2010
- Stem Cell Characteristics in Prostate Cancer Cell LinesEuropean Urology, 2010
- Evidence of Limited Contributions for Intratumoral Steroidogenesis in Prostate CancerCancer Research, 2010
- Testosterone and Dihydrotestosterone Tissue Levels in Recurrent Prostate CancerClinical Cancer Research, 2005
- The Influence of Androgen Deprivation Therapy on Dihydrotestosterone Levels in the Prostatic Tissue of Patients with Prostate CancerClinical Cancer Research, 2004
- The Androgen Axis in Recurrent Prostate CancerClinical Cancer Research, 2004
- Gene Expression Analysis of Human Prostate Carcinoma during Hormonal Therapy Identifies Androgen-Responsive Genes and Mechanisms of Therapy ResistanceThe American Journal of Pathology, 2004
- Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: Unique importance of extratesticular androgens in menThe Journal of Steroid Biochemistry and Molecular Biology, 1989
- Studies on Prostatic Cancer: I. The Effect of Castration, Of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the ProstateCA: A Cancer Journal for Clinicians, 1972